Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Former Gilead CSO Bischofberger Lands At Kronos As C-Suite Moves To Start-Ups Continue

Executive Summary

Norbert Bischofberger returns to his start-up roots, exiting Gilead after nearly 30 years to become CEO of Kronos, which is developing novel drugs directed at tough cancer targets. He's one of several big pharma/large biotech executives to venture recently into entrepreneurial opportunities.


Related Content

Harper, Hooper Exit As Amgen Revenues Rise
Harper, Hooper Exit As Amgen Revenues Rise
Pharma Q2 Results Preview: Lilly, Biogen, GSK And Gilead
'We Jumped' At Opportunity To Take On Pfizer's CAR-T Program, Allogene's Chang Says
KSQ Comes Out Of Stealth Mode With $76m And Meeker As CEO
What's Gilead Getting From Kite For Nearly $12bn?
Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role
Tony Coles's Yumanity Raises $45m To Treat Neurodegenerative Diseases
Viehbacher On Boston Pharmaceuticals: A New Model To De-Risk Drugs


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts